Stanford molecule turns lymphoma protein into a cell-death trigger
Stanford Medicine researchers designed a two-part molecule that uses BCL6, a protein that drives B-cell lymphoma, to activate the cancer cells' self-destruction pathway. In mice, twice-daily treatment made aggressive human lymphoma tumors disappear within 11 days. The team suggests the strategy could extend to other cancers and autoimmune diseases, though extensive testing remains before human use.
Stanford Medicine scientists built a compound with two binding ends. One end attaches to BCL6, a protein often driving diffuse large B-cell lymphoma, the most common non-Hodgkin lymphoma. The other end recruits P300 or CBP, proteins that add acetyl chemical tags. This rewires BCL6 from a survival factor into a signal for programmed cell death.
Normally, BCL6 briefly quiets growth-suppressing and death-promoting genes while immune cells expand; later modifications release that brake so excess cells can undergo apoptosis. In lymphoma, BCL6 can remain active, blocking death and enabling unchecked multiplication. In mice, twice-daily TCIP3 made aggressive human lymphoma tumors vanish within 11 days.
If the mouse results hold up, this strategy could eventually give patients with B-cell lymphoma another treatment route, and may be explored for other cancers or autoimmune conditions. People with aggressive B-cell lymphoma could be among those affected if human testing succeeds, but use in patients remains distant because extensive testing is still needed. Clinicians and drug developers may watch whether the molecule can be made safe, selective, and practical outside animals. For now, the impact is speculative, resting on early preclinical evidence rather than proven patient outcomes.